The combination of SP2509 with sorafenib has an obvious effect on sorafenib‐resistant hepatoma cells,17 suggesting that LSD1 inhibitors in combination with other drugs can be a promising strategy for HCC treatment. Here, KDM1A is linked to hepatocellular carcinoma.